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AIDS acquired immune deficiency syndrome
ALT  alanine aminotransferase
APHL American Public Health Laboratories
AST aspartate aminotransferase
ATS American Thoracic Society
BCG bacille Calmette-Guérin
CDC Centers for Disease Control and Prevention
DTH delayed-type hypersensitivity
DOT directly observed therapy
FDA Food and Drug Administration
HIV human immunodeficiency virus
IGRA interferon-gamma release assay
IFN-γ interferon-gamma 
INH isoniazid
LTBI latent TB infection
MDR TB multidrug-resistant tuberculosis
MMWR Morbidity and Mortality Weekly Report
NNRTIs nonnucleoside reverse transcriptase inhibitors
PI protease inhibitors
PPD purified protein derivative
QFT-G QuantiFERON®-TB Gold
QFT-GIT QuantiFERON®-TB Gold In-tube 
RIF rifampin
TB tuberculosis
TNF-α  tumor necrosis factor-alpha
T-Spot T-SPOT®.TB
TST tuberculin skin test
USPHS U.S. Public Health Service
WHO World Health Organization
inTroduCTion
This guide is intended for primary care providers who care for 
individuals and populations who may be at risk for infection with 
Mycobacterium tuberculosis. Latent tuberculosis infection (LTBI) is 
the presence of Mycobacterium tuberculosis in the body without 
signs and symptoms, or radiographic or bacteriologic evidence of 
tuberculosis (TB) disease. 
Approximately one-third of the world’s population is infected with 
M. tuberculosis. In the United States, an estimated 9–14 million 
people have LTBI. Without treatment, approximately 5–10% of 
persons with LTBI will progress to TB disease at some point in their 
lifetime. Identifying and treating those at highest risk for TB disease 
will help move toward elimination of the disease. Primary care 
providers play a key role in achieving the goal of TB elimination 
because of their access to high-risk populations.
Guidelines for testing and treating LTBI were released by the Centers 
for Disease Control and Prevention (CDC) and the American Thoracic 
Society (ATS). They can be found in the June 9, 2000 issue of 
Morbidity and Mortality Weekly Report (MMWR), entitled Targeted 
Tuberculin Testing and Treatment of Latent Tuberculosis Infection. 
Most recently, recommendations for the use of interferon-gamma 
release assays (IGRAs) were released in the June 25, 2010 issue 
of Morbidity and Mortality Weekly Report (MMWR), entitled 
Updated Guidelines for Using Interferon Gamma Release Assays to 
Detect Mycobacterium Tuberculosis Infection. References for these 
guidelines and updates can be found on page 32.
This document is not meant to be used as a substitute for the 
guidelines, but rather as a ready and useful reference that 
highlights the main points of those guidelines.
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Persons at risk for exposure to persons with TB disease include 
the following:
•	Known close contacts of a person with infectious TB disease
•	Persons who have immigrated from TB-endemic regions of the 
world (see Appendix B, p. 25)
•	Persons who work or reside in facilities or institutions with people 
who are at high risk for TB, such as hospitals that care for TB 
patients, homeless shelters, correctional facilities, nursing homes, 
or residential facilities for patients with AIDS
Also at risk are those with certain conditions and other factors 
associated with progression from LTBI to TB disease. These 
conditions and factors include:
•	HIV infection
•	 Injection drug use
•	Radiographic evidence of prior healed TB
•	Low body weight (10% below ideal) 
•	Other medical conditions, such as:
 – silicosis 
 – diabetes mellitus
 – chronic renal failure or on hemodialysis 
 – gastrectomy
 – jejunoileal bypass 
 – solid organ transplant 
 – head and neck cancer 
 – conditions that require prolonged use of corticosteroids or other 
immunosuppressive agents such as TNF-antagonists
•	Recent TST converters (persons with baseline testing results who 
have an increase of 10 mm or more in the size of the TST reaction 
within a 2-year period. The risk of progression is greatest in the 
first 1 or 2 years after infection.)
•	 Infants and children under the age of five years who have a 
positive TB test result
TargeTed TesTing for 
TuberCulosis
Targeted testing is an essential TB prevention and control strategy. 
This strategy entails finding and treating persons with LTBI who are 
at the highest risk for progressing to TB disease, and thus would 
benefit from treatment. Treatment of these high-risk individuals 
also benefits society by reducing the number of future TB cases. 
Unfocused population-based testing is not cost-effective or useful 
and leads to unnecessary treatment. TB testing activities should be 
conducted only among high-risk groups, with the intent to treat if 
LTBI is detected. Once TB disease has been excluded, treatment of 
LTBI should be offered to patients regardless of their age. 
However, there may be instances in which health care providers are 
asked to test individuals who are not necessarily regarded as high 
risk (e.g., daycare center workers, teachers, and U.S.-born students). 
A few simple questions will help health care providers assess a 
patient’s risk for LTBI. Appendix A (p. 24) contains a sample risk 
assessment tool.
Currently, there are two testing methods available for the detection 
of M. tuberculosis infection in the U.S. The tests include: 
•	Mantoux tuberculin skin test (TST) 
•	 Interferon-gamma release assays (IGRAs)
Three U.S. Food and Drug Administration (FDA) approved IGRAs are 
commercially available in the U.S.:
•	QuantiFERON®-TB Gold test (QFT-G)
•	QuantiFERON®-TB Gold-in-Tube test (QFT-GIT)
•	T.SPOT®.TB test
identifyinG Persons at risk for deveLoPinG tb disease
Generally, persons at risk for developing TB disease fall into two 
broad categories: those who have an increased likelihood of 
exposure to persons with TB disease and those with clinical 
conditions or other factors associated with an increased the 
risk of progression from LTBI to TB disease. 
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tabLe 1:
differentiating between Ltbi and tb disease
LTBI
•	 No symptoms or physical findings 
suggestive of TB disease 
•	 Positive TST or IGRA result
•	 Chest radiograph normal
•	 If done, respiratory specimens are  
smear and culture negative
TB Disease
•			Symptoms	may include one or 
more of the following: fever, 
cough, chest pain, weight loss, 
night sweats, hemoptysis, fatigue, 
and decreased appetite.
•	 TST or IGRA result usually positive
•	 Chest radiograph is usually 
abnormal. However, may 
be normal in persons with 
advanced immunosuppression or 
extrapulmonary disease.
•	 Respiratory specimens are usually 
smear or culture positive. However, 
may be negative in persons with 
extrapulmonary disease or minimal 
or early pulmonary disease.
tests for tb infection
Tuberculin Skin Test (TST)
The tuberculin skin test (TST) is used to determine if a person 
is infected with M. tuberculosis The skin test is administered 
intradermally using the Mantoux technique by injecting 0.1ml of 5 
TU purified protein derivitive (PPD) solution. If a person is infected, a 
delayed-type hypersensitivity reaction is detectable 2–8 weeks after 
infection. The reading and interpretation of TST reactions should 
be conducted within 48 to 72 hours of administration by a trained 
health care professional. For more information about tuberculin skin 
testing, visit the CDC website for additional resources (see Resources, 
p. 30) and refer to Appendix C on p. 26.
Key Points
•	The TST should not be performed on a person who has written 
documentation of either a previous positive TST result or treatment 
for TB disease.
•	Patients or family members should never measure TST results; this 
should only be done by a trained health care professional.
•	 Interpretation of the TST result is the same for persons who have 
had BCG vaccination.
•	A TST that was not measured and recorded in mm of induration 
must be repeated.
cLassification of tubercuLin skin test reactions
A TST reaction of ≥5 mm of induration is considered positive in
•	 HIV-infected persons
•	 Recent contacts of a person with infectious TB disease
•	 Persons with fibrotic changes on chest radiograph consistent with 
prior TB
•	 Organ transplant recipients
•	 Persons who are immunosuppressed for other reasons (e.g., taking 
equivalent of ≥15 mg/day of prednisone for 1 month or more or those 
taking TNF-α antagonists)
diagnosis of laTenT Tb infeCTion 
The diagnosis of LTBI is based on information gathered from the 
medical history, TST or IGRA result, chest radiograph, physical 
examination, and in certain circumstances, sputum examinations. 
The presence of TB disease must be excluded before treatment 
for LTBI is initiated (i.e., waiting for culture results if specimens 
are obtained) because failure to do so may result in inadequate 
treatment and development of drug resistance (see Table 1).
CDC discourages use of diagnostic tests for LTBI among individuals 
and populations at low risk for infection with M. tuberculosis. 
Despite CDC recommendations to the contrary, testing is sometimes 
done to meet administrative or legal requirements for groups who 
are not considered to have an increased possibility of infection in 
the absence of other factors cited above, such as persons meeting 
entrance requirements for certain schools and workplaces.
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A TST reaction of ≥10 mm of induration is considered positive in
•	 Recent immigrants (within last 5 years) from high-prevalence countries
•	 Injection drug users
•	 Residents or employees of high-risk congregate settings (prisons, jails, 
long-term care facilities for the elderly, hospitals and other health care 
facilities, residential facilities for patients with AIDS, and homeless 
shelters)
•	 Mycobacteriology laboratory personnel
•	 Persons with clinical conditions previously mentioned (see p. 7)
•	 Children younger than 4 years of age 
•	 Infants, children, or adolescents exposed to adults at high risk for TB 
disease (see p. 7)
A TST reaction of ≥15 mm of induration is considered positive in
•	 Persons with no known risk factors for TB
Although skin testing activities should be conducted only among at-risk 
groups, certain individuals may be required to have testing for employ-
ment or school attendance independent of risk. CDC and ATS do not 
recommend an approach independent of risk assessment.
Interferon–Gamma Release Assays (IGRAs)
IGRAs are used to determine if a person is infected with M. tuber-
culosis. The QuantiFERON®-TB Gold test (QFT-G), QuantiFERON®-TB 
Gold In-Tube test (QFT-GIT), and T-SPOT.®-TB are blood tests that 
measure a person’s immune reactivity to specific mycobacterial 
antigens. Specimens are mixed with peptides that simulate antigens 
derived from M. tuberculosis and controls. In a person infected 
with M. tuberculosis, the white blood cells recognize the simulated 
antigens and release interferon-gamma (IFN-γ); results are based on 
the amount of IFN-γ released.
Key Points
•	Advantages of IGRAs include the following:
 – Requires a single patient visit
 – Does not cause booster phenomenon (see p. 13)
 – Less subject to reader bias than TST
 – Unaffected by BCG and most environmental mycobacteria
•	Limitations of IGRAs include the following:
 – Blood sample must be processed within 8-16 hours
 – Limited data exist on use in groups such as children younger 
than 5 years of age, persons recently exposed to TB, immuno-
compromised persons, and those who will be tested repeatedly 
(serial testing)
Selecting a Test to Detect TB Infection
•	 IGRAs are the preferred method of testing for: 
 – Groups of people who have a poor rates of returning to have 
TST read
 – Persons who have received BCG vaccine
•	TST is the preferred method for testing for: 
 – Children under the age of 5 years
•	Either TST or IGRA may be used without preference for other 
groups that are tested for LTBI.
Key Point
•	Routine testing with both TST and IGRAs is NOT recommended.
tabLe 2:
interpretation of iGra results
IGRA test
•	 QuantiFERON® - TB Gold
•	 QuantiFERON® - TB Gold In-Tube
•	 T-SPOT ® .TB
Results reported as:
•	 Positive, negative, indeterminate
•	 Positive, negative, indeterminate
•	 Positive, negative, indeterminate, 
borderline
Note: Laboratory should provide both quantitative and qualitative test results
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sPeciaL considerations in testinG for tb infection
BCG Vaccine
The BCG (bacillus Calmette-Guerin) vaccine is currently used in 
many parts of the world where TB is common to protect infants and 
young children from serious, life-threatening disease, specifically 
miliary TB and TB meningitis. The World Health Organization (WHO) 
recommends that BCG vaccine be administered during infancy in 
TB endemic countries. BCG vaccination is not recommended in 
the U.S. The question of the effect of BCG vaccine on TST results 
often causes confusion. TST reactivity caused by BCG vaccine 
generally wanes with the passage of time, but periodic skin testing 
may prolong (boost) reactivity in vaccinated persons. A history of 
BCG vaccine is not a contraindication for tuberculin skin testing or 
treatment for LTBI in persons with positive TST results. TST reactions 
should be interpreted regardless of BCG vaccination history (see 
pages 9-10).
IGRAs use M. tuberculosis specific antigens that do not cross react 
with BCG and therefore, do not cause false positive reactions in BCG 
recipients.
HIV Infection
The risk of progression from LTBI to TB disease is 7% to 10% each 
year for those with both LTBI and untreated HIV infection. Those 
with LTBI and who are HIV negative only have a 10% risk over their 
lifetime.
 
HIV-infected persons should be tested for LTBI as soon as their 
HIV status becomes known. A negative TST or IGRA result does 
not exclude LTBI as they may have a compromised ability to react 
to tests for TB infection. Annual testing should be considered 
for HIV-infected persons who are TST or IGRA negative on initial 
evaluation and who have a risk for exposure to M. tuberculosis. 
Because the usefulness of anergy testing in HIV-infected individuals 
or others has not been demonstrated, it is not recommended. 
After the initiation of antiretroviral therapies (ART), repeat testing 
for LTBI is recommended in HIV-infected persons previously known 
to have negative TST or IGRA results as immune reconstitution may 
result in restoration of immune response.
Booster Phenomenon
Some people infected with M. tuberculosis may have a negative 
reaction to the TST if many years have passed since they became 
infected. They may have a positive reaction to a subsequent TST 
because the initial test stimulates their ability to react to the test. This 
is commonly referred to as the “booster effect” and may incorrectly 
be interpreted as a skin test conversion (going from negative to 
positive). For this reason, the “two-step method” is recommended 
at the time of initial testing for individuals who may be tested 
periodically (e.g., health care workers).  If the first TST result in the 
two-step baseline testing is positive, consider that the person is 
infected and evaluate and treat the person accordingly. If the first 
test result is negative, the TST should be repeated in 1–3 weeks. If 
the second test result is positive, consider that the person is infected 
and evaluate and treat the person accordingly; if both steps are 
negative, consider the person uninfected and classify the TST as 
negative at baseline testing (see Figure 1). 
When IGRAs are used for serial testing, there is no need for a second 
test because boosting does not occur.
fiGure 1:
two-step tuberculin skin test (tst) method
1st TST Negative Repeat TST in 1–3 weeks
2nd TST Negative Person probably does not have infection
Positive Boosted reaction due to infection in the past
Contacts
•	For contacts of a person with infectious TB disease, retesting in 
8–10 weeks is indicated when the initial TST or IGRA result is 
negative.
•	Children under the age of 5 years and immunosuppressed persons 
(e.g., HIV infected) who have a negative results should have a 
chest radiograph. If normal, treatment should be started for LTBI 
and another test performed 8–10 weeks after contact has ended.
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Sputum Examination for AFB Smear and Culture
Sputum examination is indicated for persons with positive test results 
for TB infection and either an abnormal chest radiograph or the 
presence of respiratory symptoms (even when the chest radiograph 
is normal).
Physical Examination and Medical History
Physical examination and medical history, which includes obtaining 
information about  previous positive results of a test for TB, previous 
treatment for LTBI or TB disease, and a risk assessment for liver 
disease, are indicated for an individual with positive test results. 
Written documentation of a previously positive TST or IGRA result is 
required; a patient’s verbal history is not sufficient. Appendix D  
(p. 28) provides an example of a documentation form. 
•	 If a repeat test result is positive, treatment should be continued. 
If it is negative, treatment can usually be discontinued. However, 
for some contacts at very high risk a full course of LTBI treatment 
may be recommended even in the absence of a positive TST or 
IGRA result. Consult with your local TB control program about the 
management of such contacts.
•	 In contact investigations, retesting is not called two-step testing. 
The second test is needed to determine if infection occurred but 
was too early in onset to be detected at the time of the first test.
•	 If testing is repeated, the same type of test (TST or IGRA) should 
be used.
Pregnancy
•	Test only if specific risk factors are present. (see p. 7).
•	 If a TST or IGRA reaction is positive, obtain a chest radiograph 
using proper shielding. 
otHer diaGnostic considerations
Chest Radiograph
Chest radiographs help differentiate between LTBI and pulmonary 
TB disease in individuals with positive tests for TB infection. The 
following guidelines are recommended:
•	Order a chest radiograph as part of a medical evaluation for a 
person who has a positive TST or IGRA result.
•	A chest radiograph is also indicated in the absence of a positive 
test result for TB infection when a person is a close contact of an 
infectious TB patient and treatment for LTBI will be started (i.e., 
“window prophylaxis” in a young child or immunocompromised 
person).
•	Children less than 5 years of age should have both posterior-
anterior and lateral views; all others should have at least posterior-
anterior views.
•	Other views or additional studies should be done based on the 
health care provider’s judgment.
•	Persons with nodular or fibrotic lesions consistent with old TB are 
high-priority candidates for treatment.
•	Persons with calcified granulomas only are not at increased risk for 
progression to TB disease.
•	Periodic follow-up radiographs are not indicated regardless of 
whether treatment is completed except in unusual circumstances 
(e.g., contacts to patients with MDR TB).
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sPeciaL considerations in tHe treatment of Ltbi
Contacts
Contacts are those with recent exposure to a person with known 
or suspected infectious TB (e.g., pulmonary or laryngeal TB with 
positive sputum smear). They should be evaluated immediately for 
LTBI and TB disease. If the TST or IGRA result is positive, the guidelines 
below should be followed. Those who have negative results should 
be retested in 8–10 weeks. However, if the chest radiograph is 
normal, LTBI treatment should be initiated in TST-negative 
children ≤ 5 years of age (note: some TB control programs may 
use a different age cutoff) and in immunocompromised persons 
of all ages who have negative TST or IGRA results. Treatment 
should be continued until the results of the second test and 
other medical evaluation are known. For some contacts at very 
high risk a full course of LTBI treatment may be recommended even in 
the absence of a positive TST or IGRA result. Consult with your local 
TB control program about the management of such contacts.
•	 If person is exposed to known drug-susceptible TB or drug 
susceptibility is unknown:
 – Positive TST or IGRA result → treat regardless of age with 
isoniazid (INH) for 9 months preferred
•	 If person is exposed to known isoniazid-resistant TB: 
 – Positive TST or IGRA result → treat for 4 months with rifampin (RIF)
•	 If person is exposed to known multidrug-resistant TB (MDR TB): 
 – Positive TST or IGRA result → Consult an expert in the treatment 
of multidrug-resistant TB
•	 In general, TST or IGRA-positive contacts who can provide written 
documentation of prior adequate treatment for LTBI do not need 
to be retreated. Retreatment may be indicated for persons at high 
risk of becoming reinfected and progressing to TB disease (e.g., 
young children and immunosuppressed persons)
HIV-Infected Individuals
•	HIV-infected individuals should be treated with a 9-month regimen 
of INH.
TreaTmenT of laTenT Tb infeCTion
treatment reGimens
Using an adaptation of the U.S. Public Health Service (USPHS) rating 
system, CDC and ATS have rated LTBI treatment regimens based on 
the strength of recommendation and the quality of the evidence that 















Maximum dose 300 mg
Daily x 9 months  
(270 doses)













Maximum dose 300 mg
Daily x 6 months 
(180 doses)




Maximum dose 900 mg
Twice weekly x 6 
months§
(52 doses)




Maximum dose 600 mg
Daily x 4 months  
(120 doses)
Daily x 6 months  
(180 doses)
B (II) B (III)
Note: In situations in which rifampin cannot be used (e.g., HIV-infected persons receiving protease 
inhibitors), rifabutin may be substituted.
*  Strength of the recommendation: A = preferred regimen; B = acceptable alternative; C = offer 
when A and B cannot be given
†  Quality of the supporting evidence: I = randomized clinical trials data; II = data from clinical trials 
not randomized or from other population; III = expert opinion
§  Intermittent regimen must be provided via directly observed therapy (DOT), i.e., health care 
worker observes the ingestion of medication 
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•	 Rifampin (RIF) is contraindicated in HIV-infected persons being 
treated with certain combinations of antiretroviral drugs. In those 
cases, rifabutin may be substituted for RIF (see CDC website at 
http://www.cdc.gov/tb for guidelines for the use of rifamycins and 
protease inhibitors or nonnucleoside reverse transcriptase inhibitors).
•	 If TB test result is negative, treat if HIV-infected person had recent 
exposure to infectious TB as discussed above. 
Pregnancy
•	After TB disease is excluded, consider immediate treatment for LTBI 
if the woman is HIV-infected or a recent contact, and monitor.
•	 In the absence of risk factors, wait until after the woman has 
delivered to avoid administering unnecessary medication during 
pregnancy.
•	 INH daily or twice weekly (using DOT) is the preferred regimen.
•	Supplementation with 10-25 mg/d of pyridoxine (vitamin B6) is 
recommended.
•	There is potential for an increased risk of hepatotoxicity during 
pregnancy and the first 2-3 months of the post- partum period.
•	Consider delaying treatment for LTBI until 2–3 months post-
partum unless there is a high risk of progression to TB disease 
(e.g., HIV infected, recent contact).
Breastfeeding
•	Breastfeeding is not contraindicated in women taking INH.
•	Supplementation with 10-25 mg/d of pyridoxine (vitamin B6) is 
recommended for nursing women and for breastfed infants.
•	The amount of INH in breast milk is inadequate for treatment of 
infants with LTBI.
Infants and Children
•	 Infants and children under 5 years of age with LTBI have been 
recently infected and, therefore, are at high risk for progression to 
disease.
•	Testing of adults in close social contact with the child may be 
warranted to determine whether a person with infectious TB. 
disease can be found. Consult with your local TB control program.
•	Risk of INH-related hepatitis in infants, children, and adolescents is 
minimal.
•	Routine monitoring of serum liver enzymes is not necessary unless 
the child has risk factors for hepatotoxicity (see below).
•	DOT should be considered. 
Additional Notes of Importance
•	Old fibrotic lesions can represent previous TB disease. Persons with 
TST result of ≥5 mm of induration or a positive IGRA result and no 
active disease should be treated for LTBI.
•	Calcified solitary pulmonary nodules, calcified hilar lymph 
nodes, and apical pleural capping represent healed primary M. 
tuberculosis infection and do not increase the risk of TB disease. 
The decision to treat for LTBI would be the same as for a person 
with a normal chest radiograph.
adverse effects of druGs used to treat Ltbi 
Some health care providers have concerns about treating patients for 
LTBI. These concerns are generally related to the length of treatment 
and the potential side effects of isoniazid (INH). As with any treatment, 
the health care provider must weigh the risks and benefits for each 
individual. Obtaining a detailed and accurate medical history and updating 
information at frequent intervals will identify persons who require close 
monitoring; this will aid the health care provider in determining the most 
appropriate course of action. In addition, CDC guidelines, drug package 
inserts, and other authoritative medical sources should be consulted 
whenever there is a question about side effects or drug-drug interactions.
The sections that follow discuss some of the adverse effects of 
INH and RIF, as well as recommendations for monitoring during 
treatment and for assessing and ensuring adherence. 
Possible adverse effects of INH
•	 Asymptomatic elevation of serum liver enzyme concentrations 
occurs in 10%–20% of people taking INH. Increased enzyme 
concentrations can be accepted at up to 5 times the upper limit of 
normal for patients who are free of hepatitis symptoms, if the serum 
bilirubin concentration is in the normal range. Liver enzyme concen-
trations usually return to normal even when treatment is continued.
•	Clinical hepatitis occurs in about 0.1% of people taking INH, 
and is more common when INH is combined with other agents. 
Factors that may increase either these rates or the severity of 
hepatitis include alcohol consumption, underlying liver disease or 
risks for liver disease, and the concurrent use of other medications 
which are metabolized in the liver. Symptomatic hepatitis is rare in 
patients younger than 20 years of age, but severe and fatal cases 
have been reported, and younger patients should be monitored 
clinically with the same precautions as older patients.
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•	Peripheral neuropathy occurs in less than 0.2% of people taking 
INH at conventional doses, and is more likely in the presence of 
other conditions associated with neuropathy such as diabetes, 
HIV, renal failure, and alcoholism. Pyridoxine (vitamin B6) 
supplementation is recommended in such conditions or to prevent 
neuropathy in pregnant or breastfeeding women.
Possible adverse effects of rifampin (RIF)
•	Hepatotoxicity, evidenced by transient asymptomatic 
hyperbilirubinemia, may occur in 0.6% of persons taking RIF. 
Hepatitis is more likely when RIF is combined with INH.
•	Cutaneous reactions, such as pruritis (with or without a rash), may 
occur in 6% of persons taking RIF. It is generally self-limited and 
may not be a true hypersensitivity; continued treatment may be 
possible.
•	Gastrointestinal symptoms such as nausea, anorexia, and 
abdominal pain are rarely severe enough to discontinue treatment.
•	Orange discoloration of body fluids is expected and harmless, but 
patients should be advised beforehand. Soft contact lenses may be 
permanently stained.
•	RIF interacts with a number of drugs, causing drug-drug 
interactions. It is known to reduce concentrations of methadone, 
warfarin, oral contraceptives, and phenytoin. Women using 
oral contraceptives should be advised to consider an alternative 
method of contraception.
•	RIF is contraindicated, or should be used with caution, in 
HIV-infected individuals being treated with certain protease 
inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors 
(NNRTIs). In this situation, rifabutin may be substituted.
Patient monitorinG and education durinG treatment
To ensure safe and efficacious treatment for LTBI, the health care 
provider should periodically assess the patient’s progress. This 
evaluation involves the following:
Clinical Monitoring
•	Patients should visit the health care provider who is managing 
treatment on a monthly basis for
 – Brief physical assessment for signs of hepatitis
 – Assessment of adherence
 – Review of symptoms of possible adverse drug reactions or 
interactions
•	Patients taking INH or RIF who experience possible adverse 
reactions should be advised to stop medication and consult their 
health care provider immediately.
Patient Education
•	Explain the disease process and rationale for medication in 
absence of symptoms or radiographic abnormalities.
•	Review the importance of completing treatment for LTBI.
•	Discuss possible side effects of LTBI medications such as
 – Fever
 – Unexplained anorexia 
 – Dark urine (color of coffee or cola)
 – Icterus
 – Rash
 – Persistent paresthesia of hands and feet
 – Persistent fatigue or weakness lasting 3 or more days
 – Abdominal tenderness, especially in right upper quadrant
 – Easy bruising or bleeding 
 – Arthralgia
 – Nausea 
 – Vomiting
•	Discuss management of common side effects and the need to 
report to health care provider.
Laboratory Testing
•	Baseline laboratory testing (measurements of serum AST, ALT, and 
bilirubin) are not routinely necessary
•	Laboratory testing at the start of LTBI therapy is recommended for 
patients with any of the following factors:
 – Liver disorders
 – History of liver disease (e.g., hepatitis B or C, alcoholic hepatitis, 
or cirrhosis)
 – Regular use of alcohol
 – Risks for chronic liver disease
 – HIV infection
 – Pregnancy or the immediate postpartum period (i.e., within 3 
months of delivery)
•	 Baseline testing can be considered on an individual basis, especially 
for patients taking other medications for chronic medical conditions.
•	After baseline testing, routine periodic retesting is recommended 
for persons who had abnormal initial results and other persons at 
risk for hepatic disease.
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•	 At any time during treatment, whether or not baseline tests were 
done, laboratory testing is recommended for patients who have 
symptoms suggestive of hepatitis (e.g., fatigue, weakness, malaise, 
anorexia, nausea, vomiting, abdominal pain, pale stools, dark urine, 
chills) or who have jaundice. Patients should be instructed, at the 
start of treatment and at each monthly visit, to stop taking treat-
ment and to seek medical attention immediately if symptoms of 
hepatitis develop and not to wait until a clinic visit to stop treatment.
•	AST or ALT elevations up to 5 times normal can be accepted if the 
patient is free of hepatitis symptoms, and up to 3 times normal if 
there are signs or symptoms of liver toxicity.
assessinG adHerence
Many variables affect a patient’s adherence to the medication 
regimen for treatment of LTBI. Episodes of nonadherence should be 
recognized and addressed as soon as possible. Some examples of 
barriers to adherence are noted in the section that follows.
Office-Related Variables 
•	Long waiting time for appointment and referrals
•	Long waiting time in provider’s office
•	 Inconvenient office hours
•	Complicated telephone system (not “user-friendly”)
Patient-Related Variables
•	Misinformation about topics such as 
 – The TST; for example, a positive TST result is thought to be 
normal or common in all foreign-born persons
 – Differences between injections, vaccines, and TST  
 – The words “positive” and “negative” 
 – Transmission and prevention
 – Safety of family and friends around someone with LTBI
•	Residential instability
•	Lack of financial resources
•	Poor access to health care
•	Stigma associated with tuberculosis
•	Co-existing medical conditions
•	Culture and language
•	Religious practices i.e., fasting from food
Treatment Variables
•	Complexity and duration of treatment
•	Medication side effects
•	Obtaining refills
•	Frequency of office visits
tecHniques to imProve adHerence
•	Collaborate with local health department to provide
 – DOT, especially if intermittent therapy is desirable or if patient is 
high risk (e.g., HIV infected, young child, or TB contact)
 – Case management to coordinate care and services
 – Free or low-cost medication
 – Incentives (rewards for adherence)
 – Grocery store or restaurant vouchers
 – Nutritional supplements
 – Cell phone minutes
 – Movie tickets
 – Enablers (to overcome barriers)
 –  Free van transportation or bus tickets
 – Effective patient education 
•	Provide patient education and instructions in patient’s primary 
language
•	Reinforce patient education at each visit
•	Ensure confidentiality
•	Suggest or provide patient reminders such as pill box, calendar, 
timer
Post-treatment foLLow-uP
•	Patient should receive documentation of TST or IGRA results and 
treatment completion that includes name, dates, chest radiograph 
result, and dosage and duration of medication. The patient should 
be instructed that he or she should present this document any 
time future testing is required.
•	Providers should re-educate patient about the signs and symptoms 
of TB disease and advise them to contact the medical provider if 
he or she develops any of these signs or symptoms.
•	Regardless of whether the patient completes treatment for LTBI, 
serial or repeat chest radiographs are not indicated unless the 
patient develops signs or symptoms suggestive of TB disease. 
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appendix a 
samPLe tb risk assessment tooL
Persons with any of the following risk factors should be tested for TB infec-
tion unless there is written documentation of a previous positive TST or IGRA 
result.
Risk Factor 
Recent close or prolonged contact with someone with 
infectious TB disease
Foreign-born person from or recent traveler to 
high-prevalence area 
Chest radiographs with fibrotic changes suggesting 
inactive or past TB
HIV infection
Organ transplant recipient
Immunosuppression secondary to use of prednisone 
(equivalent of ≥15 mg/day for ≥1 month) or other 
immunosuppressive medication such as TNF-α antagonists 
Injection drug user
Resident or employee of high-risk congregate setting (e.g., 
prison, long term care facility, hospital, homeless shelter)
Medical conditions associated with risk of progressing 
to TB disease if infected (e.g., diabetes mellitus, silicosis, 
cancer of head or neck, Hodgkin’s disease, leukemia, and 
end-stage renal disease, intestinal bypass or gastrectomy, 
chronic malabsorption syndrome, low body weight [10% 
or more below ideal for given population])
























Adapted from a form developed by Minnesota Department of Health TB 
Prevention and Control Program
appendix b
identifyinG Persons from HiGH-risk countries
•	 Local epidemiologic profiles are the most useful resource to identify 
countries of highest risk. Health care providers should base testing and 
treatment decisions on local immigration patterns and epidemiology.
•	 In 2009, approximately 60% of TB cases in the United States occurred in 
foreign-born individuals.
•	 The majority of U.S. cases among foreign-born individuals are in people 
from seven countries (Mexico, Philippines, Vietnam, India, China, Haiti, 
and Guatemala).
•	 For a list of high burden countries and profiles of these countries, see the 
Stop TB Partnership website: http://www.stoptb.org/countries/tbdata.asp 
– Note that the ranking of countries changes yearly.
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Recording and documentation
•	 Record date TST was administered.
•	 Record the brand name of the PPD solution, lot number, manufacturer, 
and expiration date on the patient record.
•	 Record results in millimeters of induration (0 mm if there is no induration) 
rather than as positive or negative.
•	 Record date and time of reading and name of person reading TST.
•	 Provide patient and ordering health care provider with written 
documentation.
Storage and Handling
•	 PPD solution must be kept refrigerated at 36°– 46° F.
•	 Avoid fluctuations in temperature; do not store on the refrigerator door.
•	 Syringes must be filled immediately prior to administration.
•	 Store and transport the tuberculin in the dark as much as possible and 
avoid exposure to light.
•	 Tuberculin testing solution should not be stored with other vials, such as 
Tdap, that could be mistaken for PPD.
*  Contact the local health department TB program for training on the 
Mantoux tuberculin skin test.
appendix C  
administration and measurement of tHe tst*
Administration
The Mantoux test is the recommended TST. It is administered by injecting 
0.1 ml of 5 TU of purified protein derivative (PPD) solution intradermally into 
the volar surface of the forearm using a 27-gauge needle with a tuberculin 
syringe.
•	 Obtain results of all previous TST. Ask patient to describe what the test 
area looked like 2–3 days after administration. Written documentation 
must be obtained for history to be applicable.
•	 Avoid areas of skin with veins, rashes, or excess hair.
•	 Cleanse the area with alcohol swab, allow area to dry, and inject all 
antigen just below the surface of the skin on the volar surface of the 
forearm, forming a 6–10 mm wheal (a pale, raised area with distinct 
edges; has orange-peel appearance and does not disappear immediately).
•	 If no wheal forms, or if a wheal forms that is less than 6 mm of 
induration, the test should be repeated immediately, approximately 2 
inches from original site or on the other arm.
•	 If minor bleeding occurs, dab the injection site with a cotton swab.
•	 Avoid covering the area with a bandage or applying pressure to the 
injection site.
•	 Record the date, time, and location of the TST.
•	 Instruct patient not to scratch the site, but to use cool compress to relieve 
any itching or swelling.
•	 Inform patient of the importance of returning for a reading of the TST 
within 48–72 hours (2–3 days).
•	 Give written appointment card for TST reading.
•	 Provide written information about TST (pamphlet or brochure).
Measurement 
•	 Measure the induration (hard bump) rather than erythema. 
•	 Plpate area with fingertips, measuring the diameter of induration 
perpendicular to the long axis of the arm.
•	 Use ballpoint pen to mark edges of induration.
•	 Use a tuberculin skin testing ruler or ruler with millimeters to measure the 
distance between the two points.
28 29
Record of Treatment Completion 
To Whom It May Concern:
The following is a record of evaluation and treatment for M. tuberculosis 
infection: 
Name: ______________________________ Date of birth: ________________
TST: Date: _________________Results (in millimeters of induration): _______
IGRA: Date: _______________ Type of test: __________ Result: ___________ 
Chest radiograph: Date: _______________ Results: _____________________  
 
Date medication started: ______________ Date completed: ______________  
Medication(s): ____________________________________________________
 ________________________________________________________________
This person is not infectious. He/she may always have a positive TB skin test, 
so there is no reason to repeat the test. If you need any further information, 
please contact this office.




Record of TB Skin Test
To Whom It May Concern:
The following is a record of Mantoux tuberculin skin testing:
Name: ______________________________ Date of birth: ________________
Date and time test administered: _____________________________________
Administered by: __________________________________________________
Manufacturer of PPD: ______________________________________________
Expiration date: ______________________ Lot Number: _________________
Date and time test read: _______________ Read by: ____________________
Date: ____________________________________________________________
Results (in millimeters _________________
Record of Interferon-Gamma Release Assay for TB
To Whom It May Concern: __________________________________________
The following is a record of IGRA results:
Name: ___________________________________________________________
Date of birth: _____________________________________________________
Type of test: _________________________ Date: _______________________
Laboratory: _______________________________________________________
Qualitative result: _____________________ Nil (IU IFN-γ): _________________
Mitogen (IU IFN-γ): ____________    M. tb antigens (IU IFN-γ): _____________
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educationaL materiaLs for HeaLtH care Providers*
•	 Mantoux Tuberculin Skin Testing Products  
(Centers for Disease Control and Prevention)
•	 Management of LTBI in Children and Adolescents  
(NJMS Global Tuberculosis Institute, 2009)
•	 Fact Sheets
 – Targeted Tuberculin Testing and Interpreting Tuberculin Skin Test Results 
 – Treatment of Latent Tuberculosis Infection: Maximizing Adherence 
 – Treatment Options for Latent Tuberculosis Infection 
 – Interferon-Gamma Release Assay (IGRAs)
(Centers for Disease Control and Prevention)
•	 Slide Set
 – Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infec-
tion: Applying CDC/ATS Guidelines in Your Clinical Practice
(Centers for Disease Control and Prevention)
*  CDC education and training materials may be viewed, downloaded, and 
ordered online at http://www.cdc.gov/tb.
state HeaLtH dePartment tb ProGram
Phone: __________________________________________________________  
Fax: _____________________________________________________________ 





Centers for Disease Control and Prevention (CDC)
Division of Tuberculosis Elimination
http://www.cdc.gov/tb




reGionaL traininG and medicaL consuLtation centers 
(rtmccs)
•	 Francis J. Curry National Tuberculosis Center  
Website: http://www.nationaltbcenter.edu 
Phone: 415-502-4600 
Serving Alaska, California (Los Angeles, San Diego, and San Francisco), 
Colorado, Hawaii, Idaho, Montana, Nevada, Oregon, Utah, Washington, 
Wyoming, and the U.S. Affiliated Pacific Islands (USAPI).
•	 Heartland National Tuberculosis Center 
Website: http://www.heartlandntbc.org 
Phone: 1-800-839-5864  
Serving Arizona, Illinois (Chicago), Iowa, Kansas, Minnesota, Missouri, 
New Mexico, Nebraska, North Dakota, Oklahoma, South Dakota, Texas 
(Houston), and Wisconsin.
•	 New Jersey Medical School – Global Tuberculosis Institute 
Website: http://www.umdnj.edu/globaltb 
Phone: 973-972-3270  
Serving Connecticut, District of Columbia, Delaware, Indiana, Massa-
chusetts, Maryland (Baltimore City), Maine, Michigan (Detroit), New 
Hampshire, New Jersey, New York (New York City), Ohio, Pennsylvania 
(Philadelphia), Rhode Island, Vermont, and West Virginia.
•	 Southeastern National Tuberculosis Center 
Website: http://sntc.medicine.ufl.edu 
Phone: 352-265-7682 
Serving Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missis-
sippi, North Carolina, South Carolina, Tennessee, Virginia, Puerto Rico, 
and the U.S. Virgin Islands.
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